Aktis Oncology, Inc. (AKTS)

Aktis Oncology Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Revenue	5.56	1.49	-	-
Cost of Revenue	63.56	40.95	25.92	-
Gross Profit	-58	-39.47	-25.92	-
Selling, General & Admin	14.94	12.58	8.88	5.46
Research & Development	-	-	-	14.3
Operating Expenses	14.94	12.58	8.88	19.76
Operating Income	-72.94	-52.05	-34.79	-19.76
Interest & Investment Income	12.34	8.1	5.38	1.65
Other Non Operating Income (Expenses)	-0.05	-0.03	0.78	0.19
Pretax Income	-60.65	-43.98	-28.64	-17.93
Net Income	-60.65	-43.98	-28.64	-17.93
Net Income to Common	-60.65	-43.98	-28.64	-17.93
Shares Outstanding (Basic)	1	1	1	1
Shares Outstanding (Diluted)	1	1	1	1
Shares Change (YoY)	53.35%	14.46%	18.90%	-
EPS (Basic)	-76.44	-62.46	-46.55	-34.65
EPS (Diluted)	-76.44	-62.46	-46.55	-34.65
Free Cash Flow	-69.34	11.9	-33.77	-20.43
Free Cash Flow Per Share	-87.40	16.90	-54.89	-39.49
Operating Margin	-1311.94%	-3500.34%	-	-
Profit Margin	-1090.81%	-2957.63%	-	-
Free Cash Flow Margin	-1247.19%	800.27%	-	-
EBITDA	-70.87	-50.48	-33.67	-19.32
D&A For EBITDA	2.08	1.58	1.12	0.45
EBIT	-72.94	-52.05	-34.79	-19.76

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q